Core Viewpoint - He Yuan Bio (688765) anticipates a net profit loss of between 143 million yuan and 167 million yuan for the year 2025, despite rapid revenue growth from its product Aofumin (recombinant human albumin injection) entering the market [1] Group 1: Financial Performance - The company projects a net profit loss of -143 million to -167 million yuan for 2025 [1] - The overall performance remains in a loss state due to various factors, including ongoing high R&D investments [1] Group 2: Product Development and Market Entry - Aofumin has been approved for market entry, contributing to rapid revenue growth [1] - The production line for the recombinant human albumin is still in the capacity ramp-up phase, with gradual capacity release expected [1]

Core Viewpoint - He Yuan Bio (688765.SH) expects a net profit attributable to shareholders of the parent company to be between -167 million and -143 million yuan for the year 2025 [1] Group 1: Financial Performance - The main reason for the performance change is the rapid growth in sales revenue following the approval and market introduction of the product Aofumin (recombinant human albumin injection) [1] - The production line for the annual output of 10 tons of recombinant human albumin raw liquid and preparations is still in the capacity ramp-up phase, with capacity expected to be gradually released [1] - Despite these factors, the company remains in a state of overall performance loss due to continued high levels of R&D investment [1]

Group 1 - The biopharmaceutical sector experienced a decline of 1.98% on January 28, with Baipusais leading the drop [1] - The Shanghai Composite Index closed at 4151.24, up 0.27%, while the Shenzhen Component Index closed at 14342.9, up 0.09% [1] - Notable gainers in the biopharmaceutical sector included Kanghua Biological, which rose by 3.02% to a closing price of 74.70, and Liaoning Chengda, which increased by 2.55% to 12.86 [1] Group 2 - Baipusais saw a significant drop of 10.57%, closing at 58.18, with a trading volume of 57,400 shares and a transaction value of 342 million [2] - Other notable decliners included Kangla Weishi, down 6.16% to 10.97, and Jinchuan Protein, down 5.90% to 46.58 [2] - The biopharmaceutical sector experienced a net outflow of 1.252 billion in main funds, while retail investors saw a net inflow of 653 million [2] Group 3 - Rongchang Biological had a net inflow of 38 million from main funds, representing 6.49% of its total, while it faced a net outflow of 58.99 million from retail investors [3] - Liaoning Chengda also saw a net inflow of 14.86 million from main funds, but a net outflow of 15.01 million from retail investors [3] - The overall trend indicates a mixed sentiment in the biopharmaceutical sector, with main funds withdrawing while retail investors are actively buying [3]

格隆汇1月28日丨禾元生物(688765.SH)公布，经财务部门初步测算，预计2025年年度实现利润总 额-16,700万元到-14,300万元，预计2025年年度实现归属于母公司所有者的净利润-16,700万元到-14,300 万元。预计归属于母公司所有者的扣除非经常性损益后的净利润为-19,100万元到-16,200万元。预计 2025年年度实现营业收入4,500万元到5,000万元，同比增加78.46%到98.29%，扣除与主营业务无关的业 务收入和不具备商业实质的收入后的营业收入为4,500万元到5,000万元。 本期业绩变化的主要原因：（一）报告期内，随着公司产品奥福民（通用名称：重组人白蛋白注射液 （水稻））获批上市并进入市场导入阶段，销售收入实现快速增长。（二）目前，相关产品所在的年产 10吨重组人白蛋白原液及制剂cGMP智能化生产线仍处于产能爬坡期，产能将逐步释放。（三）与此同 时，公司继续保持高强度的研发投入。受上述因素共同影响，报告期内公司整体仍处于业绩亏损状态。 ...

南财智讯1月28日电，禾元生物发布年度业绩预告，预计2025年全年归属于上市公司股东的净利润 为-16,700万元到-14,300万元，即净亏损1.43亿元—1.67亿元；预计2025年全年归属于上市公司股东的扣 除非经常性损益的净利润为-19,100万元到-16,200万元。报告期内，随着公司产品奥福民（通用名称： 重组人白蛋白注射液（水稻））获批上市并进入市场导入阶段，销售收入实现快速增长；目前，相关产 品所在的年产10吨重组人白蛋白原液及制剂cGMP智能化生产线仍处于产能爬坡期，产能将逐步释放； 与此同时，公司继续保持高强度的研发投入。受上述因素共同影响，报告期内公司整体仍处于业绩亏损 状态。 ...

证券代码：688765 证券简称：禾元生物 公告编号：2026-001 武汉禾元生物科技股份有限公司 2025 年年度业绩预告 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现利润总额-16,700 万元到 -14,300 万元，预计 2025 年年度实现归属于母公司所有者的净利润-16,700 万元 到-14,300 万元。 （2）预计归属于母公司所有者的扣除非经常性损益后的净利润为-19,100 万 元到-16,200 万元。 （3）预计 2025 年年度实现营业收入 4,500 万元到 5,000 万元，同比增加 78.46%到 98.29%，扣除与主营业务无关的业务收入和不具备商业实质的收入后 的营业收入为 4,500 万元到 5,000 万元。 （三）本次业绩预告未经注册会计师审计。 二、上年同期业绩情况和财务状况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 受上述因素共同影响 ...

Group 1 - The core viewpoint of the news is that He Yuan Bio experienced a slight increase in stock price and notable changes in financing activities on January 27, with a net financing outflow [1] - On January 27, He Yuan Bio's stock rose by 0.85%, with a trading volume of 217 million yuan, and a financing buy-in amount of 16.12 million yuan, while the financing repayment was 25.13 million yuan, resulting in a net financing outflow of 9.01 million yuan [1] - As of January 27, the total balance of margin trading for He Yuan Bio was 262 million yuan, which represents 7.72% of its circulating market value [1] Group 2 - As of October 28, the number of shareholders for He Yuan Bio reached 47,100, marking an increase of 84,075% compared to the previous period, while the average circulating shares per person decreased by 99.85% to 869 shares [2] - For the period from January to September 2025, He Yuan Bio reported an operating income of 19.66 million yuan, reflecting a year-on-year decrease of 8.51%, and a net profit attributable to the parent company of -121 million yuan, also a decrease of 8.44% year-on-year [2]

Group 1 - The core viewpoint of the news is that He Yuan Bio has seen a continuous increase in stock price, with a 6.57% rise over three days, reaching a price of 83.00 yuan per share and a market capitalization of 29.673 billion yuan [1] - He Yuan Bio, established on November 16, 2006, specializes in the research, production, and sales of plant-derived human serum albumin using rice endosperm cell recombinant protein expression technology, with 75.44% of its revenue coming from recombinant human albumin [1] - The stock has a trading volume of 2.17 billion yuan and a turnover rate of 6.52% as of the report date [1] Group 2 - According to data, the Industrial Bank of China Credit Fund holds He Yuan Bio as its fifth-largest position, with 16,500 shares representing 0.02% of the fund's net value, yielding a floating profit of approximately 11,500 yuan today and 84,300 yuan over the three-day increase [2] - The fund, named Industrial Bank of China Science and Technology ETF Link A (011614), was established on March 5, 2021, with a current scale of 1.494 billion yuan and has achieved a year-to-date return of 13.15% [2] - The fund's one-year return is 54.14%, ranking 42 out of 209 in its category, while its total return since inception is 19.72% [2] Group 3 - The fund manager of Industrial Bank of China Science and Technology ETF Link A is Zhao Xu, who has a total tenure of 14 years and 106 days, managing assets totaling 68.885 billion yuan [3] - During Zhao Xu's tenure, the best fund return achieved was 233.59%, while the worst return was -84.87% [3]

Core Viewpoint - The company has exceeded 9,000 acres in medicinal rice cultivation and plans to gradually expand planting areas to match production capacity needs [1] Group 1: Company Operations - The company has completed the main structure of its 120-ton recombinant human albumin production line, with some equipment already in testing and others being gradually commissioned [1]

Group 1 - The company, Betta Pharmaceuticals, announced a commercial cooperation with Wuhan Heyuan Biotechnology Co., Ltd. for the regional commercialization of recombinant human albumin injection (rice-based) [1] - The recombinant human albumin product is considered groundbreaking, with clinical research showing efficacy comparable to human plasma albumin while overcoming safety risks associated with blood sources [1] - The company holds a 5.6% stake in Heyuan Biotechnology, which is currently under a lock-up period lasting one year post-IPO [1]